TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Researchers studying human brain tissue and mice found that lower levels of the protective protein NRF2 in oligodendrocytes were associated with faster cognitive decline and abnormalities in myelin and nerve fibers. The mouse experiments support a possible causal role, but the findings do not show that NRF2-targeting drugs prevent age-related decline in people.
Researchers have linked lower NRF2 levels in oligodendrocytes, brain cells that maintain nerve insulation, with faster cognitive decline in older adults. In a study published in Nature Medicine, analyses of human brain tissue and experiments in mice connected changes in these cells to abnormal myelin and loss of large nerve fibers, pointing to a possible biological pathway for age-related decline.
The researchers, from the University of Edinburgh and the UK Dementia Research Institute, studied participants in the Lothian Birth Cohort 1936, whose cognitive abilities had been tracked over many years. Of 1,091 people enrolled, 866 completed additional testing after age 70. Assessments between ages 70 and 82 measured memory, information-processing speed and spatial reasoning. Most participants experienced some decline, but the pace varied.
When the team examined brain tissue collected after death from a subset of participants, greater decline over time was associated with fewer large nerve fibers and abnormal buildup of myelin, the fatty coating that helps electrical signals travel along nerve fibers. These tissue features were linked to the rate of decline, rather than simply to a person’s cognitive test performance at one age.
The study focused on oligodendrocytes, which make and maintain myelin. People with more severe decline had lower levels of NRF2 in these cells. In mice, researchers reduced NRF2 specifically in oligodendrocytes; the animals developed excessive myelin, lost large nerve fibers and showed smaller improvements in cognitive performance as they aged. The experiments support a role for NRF2 in maintaining cell function, but do not establish that the same chain of effects explains cognitive decline in people.
A Possible Target in Aging Brains
The findings add a potential mechanism to research on cognitive aging: cells that usually support nerve communication may become impaired and contribute to damage when their protective systems falter. This challenges a simple view of oligodendrocytes as consistently beneficial, while not suggesting that myelin itself is generally harmful. The reported abnormalities concern age-related changes in myelin and nerve fibers.
NRF2 is of interest because drugs acting on its pathway are already used for other neurological conditions, including multiple sclerosis. The study raises the possibility that this pathway could be investigated as a way to protect brain function. It does not show that an existing drug treats or prevents cognitive decline in older adults; testing safety and benefit for that purpose would require further research.
As an affiliate, we earn on qualifying purchases.
From Long-Term Testing to Brain Tissue
The Lothian cohort offered researchers a way to compare biological findings with changes in cognition across later life, rather than relying only on a single test. The participants’ assessments covered multiple abilities, and the variation in their rates of decline helped the team look for differences associated with faster change.
The research combined that human evidence with experiments in mice. The human analysis identified associations in post-mortem tissue; the mouse work tested what happened when NRF2 was reduced in oligodendrocytes. Together, those approaches provide evidence for a possible pathway, but they have different limits: mouse results cannot by themselves establish what causes cognitive decline in people.
“As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.”
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital, part of Unity Health Toronto
As an affiliate, we earn on qualifying purchases.
Human Treatment Evidence Is Missing
The study does not establish whether low NRF2 activity is a cause of cognitive decline in people, a consequence of other aging processes, or part of a more complex relationship. The mouse experiments show that reducing NRF2 in oligodendrocytes can produce related changes in animals, but they cannot confirm the same effects in humans.
It also remains unknown whether medicines that affect NRF2 can safely preserve cognition in older adults, which patients might benefit, or what dose and timing would be appropriate. The source report does not provide clinical trial results testing such drugs for age-related cognitive decline. The findings should not be treated as evidence that people should take an existing medication for this purpose.
cognitive decline support supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Testing the NRF2 Pathway
The next step is to determine how NRF2 activity changes in oligodendrocytes during human aging and whether that change can be modified without causing harm. Researchers would also need to test whether treatments aimed at the pathway improve relevant outcomes in people, rather than relying on cognitive changes observed in mice or findings from multiple sclerosis research.
Until such studies are completed, the work identifies a possible research target, not a proven prevention or treatment. No clinical timetable or planned trial for age-related cognitive decline is specified in the report.
As an affiliate, we earn on qualifying purchases.
Key Questions
What are oligodendrocytes?
Oligodendrocytes are brain cells that produce and maintain myelin, the insulating coating around nerve fibers that helps electrical signals travel.
What did researchers find about NRF2?
In human brain tissue, more severe cognitive decline was associated with lower NRF2 levels in oligodendrocytes. In mice, reducing NRF2 in these cells led to abnormal myelin, loss of large nerve fibers and smaller improvements in cognitive performance with age.
Does the study prove that NRF2 changes cause cognitive decline in people?
No. The human findings are associations. Mouse experiments support a possible mechanism, but do not prove causation in people.
Can an existing drug prevent age-related cognitive decline?
The report says drugs that act on the NRF2 pathway are used for other conditions, including multiple sclerosis. It does not report evidence that these drugs prevent or treat age-related cognitive decline; that would need to be tested directly.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
